Cost of Parkinson's disease. A retrospective 3-month analysis of direct costs;Krankheitskosten der Parkinson erkrankung. Eine retrospektive dreimonatige analyse der direkten kosten

Nervenarzt

Volumn 68, Issue 12, 1997, Pages 978-984

  Dodel, R C ^a,b   Singer, M ^a   Kohne Volland R ^c   Selzer, R ^d   Scholz, W ^e   Rathay, B ^e   Oertel, W H ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c Gesell fur Statistik und Consulting   (Germany)

^d Hoffmann LaRoche ^*  (Germany)

^e ROCHE INNOVATION CENTER MUNICH   (Germany)

Author keywords

Cost of illness; Motor fluctuations; Parkinson's disease

Indexed keywords

APOMORPHINE; BENSERAZIDE; BROMOCRIPTINE; CARBIDOPA; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; LISURIDE; PERGOLIDE; SELEGILINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DYSKINESIA; FEMALE; GERMANY; HEALTH CARE COST; HOSPITAL CARE; HUMAN; MALE; OUTPATIENT CARE; PARKINSON DISEASE; PHYSIOTHERAPY; RETROSPECTIVE STUDY;

AGED; AMBULATORY CARE; ANTIPARKINSON AGENTS; COST OF ILLNESS; CROSS-SECTIONAL STUDIES; DIRECT SERVICE COSTS; DISABILITY EVALUATION; FEMALE; GERMANY; HUMANS; MALE; NATIONAL HEALTH PROGRAMS; PARKINSON DISEASE; PATIENT ADMISSION; PATIENT CARE TEAM; PHYSICAL THERAPY MODALITIES; RETROSPECTIVE STUDIES;

EID: 0031437996     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001150050226     Document Type: Article

References (34)

1. Bundesminister für Arbeit und Sozialordnung (1992) Arbeitsunfähigkeit und Kranken-hausbehandlung nach Krankheitsarten 1989. Bundesministerium, Bonn
2. Cockerell OC, Hart YM, Sander JW, Shorvon SD (1994) The cost of epilepsy in the United Kingdom: an estimation based on the results of two population-based studies. Epilepsy Res 18:249-60
3. de Jong GJ, Meerwaldt JD, Schmitz PIM (1987) factors that influence the occurence of response variations in Parkinson's disease. Neurology 22:4-7
4. Dodel RC, Eggert K, Oertel WH (1994) Costs of Parkinson's disease - a preliminary study. in:Stern MB (ed) Beyond the decade of the brain. Wells Medical, Kent, pp 59-73
5. Dodel RC, Eggert KM, Singer MS, Eichhom TE, Pogarell O, Oertel WH (1997) Costs of drug treatment in Parkinson's disease. Mov Disord (in press)
6. Ernst RL, Hay JW (1994) The US economic and social costs of Alzheimer's disease revisited. Am J Public Health 84:1261-1264
7. Gibb WRG, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease, J Neurol Neurosurg Psychiatry 51:745-752
8. Goetz CG, Stebbins GT, Chmura TA, Fahn S, Klawans HL, Marsden CD (1995) Teaching tape for the motor secton of the unified Parkinson's disease rating scale. Mov Disord 10:263-266
9. Haycock J (1992) Idiopathic Parkinson's disease: the burden of illness. Med Sc Thesis, University of York, York
10. Hoehn M,Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427-442
11. Jönssen B, Rehnberg C, Borgquist L et al. (1994) Locomotion status and costs in destructive rheumatoid arthritis: a comprehensive study of 82 patients from a population of 13000. Acta Orthop Scand 63:207-212
12. Kleinhenz J, Vieregge P, Fassl H, Jorg J (1990) Prävalenz des Morbus Parkinson in der Bundesrepublik Deutschland. Off Gesundheitswes 52:181-190
13. Kurlan R, Clark S, Shoulson I, Penney JB, Parkinson Study Group Rochester and Ann Arbor (1988) Economic impact of protective therapy for early Parkinson's disease. Ann Neurol 24:153
14. Maier-Hoehn MM (1992) The natural history of Parkinson's disease in the pre-levodopa and post-levodopa eras. Neurologic Clinics 30:331-339
15. Marsden CD (1990) Parkinson's disease. Lancet 335:948-952
16. Max W (1996) The costs of Alzheimer's disease. Pharmacoeconomics 9:5-10
17. McDermott MP, Jankovic J, Carter J, Fahn S, Gauthier S, Goetz CG, Golbe LI, Koller W, Lang AE, Weiner WJ, Parkinson Study Group (1995) Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. Arch Neurol 52:565-570
18. Mutch WJ, Strudwick A, Roy SK, Downie AW (1986) Parkinson's disease. Disability, review, and management. Br Med J 293:675-677
19. O'Brien B (1987) Multiple sclerosis. Office of health economics, London
20. Oertel WH, Quinn NP (1996) Parkinsonism. In:Brandt T, Diener HC, Caplan LR, Kennard C, Dichgans J (eds) Neurological disorders: course and treatment. Academic Press, San Diego, pp 715-772
21. Poewe W, Gerstenbrand F (1986) Klinische Klassifikation des Parkinson-Syndroms - Subtypen und Übergänge zu Multi-System-Atrophien, In:Schnabert G, Auff E (Hrsg) Das Parkinson-Syndrom. Editiones Roche, Frankfurt, pp 39-46
22. Schwabe U (1995) Parkinsonmittel. In: Schwabe U, Paffrath D (Hrsg) Arzneiverord-nungsreport'95. G Fischer, Stuttgart Jena, pp 357-359
23. Singer E (1973) Social costs of Parkinson's disease. J Chron Dis 26:243-254
24. Späte HF, Gemende G, Gemende I (1988) Psychosoziale Aspekte der Langzeitbe-treuung von Parkinsonkranken. Psychiatr Neurol Med Psychol 40:385-394
25. Stamm T, Spycher S, Engfer A, Fahrenkrug E (1996) Krankheitskosten des Morbus Parkinson in Deutschland. Psycho 22:212-228
26. Stewart WF, Lipton RB (1994) The economic and social impact of migraine. Eur Neurol 34 [Suppl 2]:12-17
27. Sutcliffe RLG, Prior R, Mawby B, McQuillan WJ (1985) Parkinson's disease in the district of the Northampton Health Authority, United Kingdom. A study of prevalence and disability. Acta Neurol Scand 72:363-379
28. Szucs T (1996) Was ist medizinische Ökonomie. Med Klinik 91 49-53
29. Tandberg E, Larsen JP, Nessler EG, RiiseT, Aarli JA (1995) The epidemiology of Parkinson's disease in the county of Rogaland, Norway. Mov Dis 10:541-549
30. Trenkwalder C, Schwarz J, Gebhard J, Ruland D, Trenkwalder P, Hense HW, Oertel WH (1995) Starnberg trial on epidemiology of parkinsonism and hypertension in the elderly. Arch Neurol 52:1017-1022
31. Vieregge P, Kortke D, Meyer-Bornsen C (1994) Ärztliche Betreuung und soziale Situation älterer Parkinson-Patienten. Z Gerontol 27:260-269
32. Weinfeld FD, Baum HM (1984) The national multiple sclerosis survey. Background and economic impact Ann NY Acad Sci 436:469-471
33. Wiksten B, Aquilonius SM, Haggblom O, Johansson K (1994) High prevalence of Parkinson's disease in the county of Gävleborg, Sweden. New Trends Clin Neuropharmacol 8:186
34. Ziegler M, Levy E (1990) Approche économique du coût de traitement de la maladie de Parkinson. Ann Psychiatr 54:348-353